Kathy Deng M.D.

Recommended Articles

• Astonishing Clinical Trial Results Show Promise for Non-Hodgkin Lymphoma Research

  There’s good news for those who’ve been diagnosed with the aggressive non-Hodgkin lymphoma (NHL) type referred to as diffuse large-B cell (DLBCL). According to the American Cancer Society (ACS), this type of HNL is the most common type of lymphoma.The descriptive letters clarify the type of...

• The Effect of Sunshine on Lymphoma

  Having a lack of enough vitamin D can drastically effect one's ability to fight many cancers, including lymphoma. So, researchers inevitably wondered whether the addition of Vitamin D to preexisting therapies would prolong patients' lives. The Wilmot Cancer Institute received a $3 million grant for...

• The Link Between Melatonin and Lymphoma

  There’s always room for improvement when it comes to the experience and outcomes of cancer treatment. Fortunately, scientists are constantly researching new, better ways to do so. Although standard treatment remains mostly the same for now, the medical community is making great strides in...

• 9/11 Ground Zero Worker's Lymphoma Improves with Clinical Trial

  When the terrorist attacks occurred in New York on September 11th, 2001, Bart Zagami, a 61-year-old New York State Supreme Court officer, was in his office just a few blocks away from the World Trade Center in lower Manhattan. Days after the 9/11 terrorist attacks, Zagami spent his time at Ground...

• Seven-year-old Lymphoma Ninja Warrior Fights Through 500 Days of Chemo

  In some ways, Von Kleiv is an ordinary 7-year-old boy. He goes to Welch Elementary School in Dover, Delaware. He’s in second grade. He’s getting into karate, and just broke his first wooden board at his first demonstration. People know him as a boy warrior with a strong spirit. He is optimistic,...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...